Analysis of genetic variations in cancer

The aim of this thesis is to apply recently developed technologies for genomic variation analyses, and to ensure quality of the generated information for use in preclinical cancer research. Faster access to a patients’ full genomic sequence for a lower cost makes it possible for end users such as cl...

Full description

Bibliographic Details
Main Author: Hasmats, Johanna
Format: Doctoral Thesis
Language:English
Published: KTH, Genteknologi 2012
Subjects:
DNA
RNA
Online Access:http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-104438
http://nbn-resolving.de/urn:isbn:978-91-7501-450-0
id ndltd-UPSALLA1-oai-DiVA.org-kth-104438
record_format oai_dc
spelling ndltd-UPSALLA1-oai-DiVA.org-kth-1044382014-02-12T04:47:12ZAnalysis of genetic variations in cancerengHasmats, JohannaKTH, GenteknologiKTH, Science for Life Laboratory, SciLifeLabStockholm2012CancerMutationsVariationsSingle Nucleotide PolymorphismDNARNAGenomeMassively Parallel SequencingExome SequencingToxicityThe aim of this thesis is to apply recently developed technologies for genomic variation analyses, and to ensure quality of the generated information for use in preclinical cancer research. Faster access to a patients’ full genomic sequence for a lower cost makes it possible for end users such as clinicians and physicians to gain a more complete understanding of the disease status of a patient and adjust treatment accordingly. Correct biological interpretation is important in this context, and can only be provided through fast and simple access to relevant high quality data. Therefore, we here propose and validate new bioinformatic strategies for biomarker selection for prediction of response to cancer therapy. We initially explored the use of bioinformatic tools to select interesting targets for toxicity in carboplatin and paclitaxel on a smaller scale. From our findings we then further extended the analysis to the entire exome to look for biomarkers as targets for adverse effects from carboplatin and gemcitabine. To investigate any bias introduced by the methods used for targeting the exome, we analyzed the mutation profiles in cancer patients by comparing whole genome amplified DNA to unamplified DNA. In addition, we applied RNA-seq to the same patients to further validate the variations obtained by sequencing of DNA. The understanding of the human cancer genome is growing rapidly, thanks to methodological development of analysis tools. The next step is to implement these tools as a part of a chain from diagnosis of patients to genomic research to personalized treatment. <p>QC 20121105</p>Doctoral thesis, comprehensive summaryinfo:eu-repo/semantics/doctoralThesistexthttp://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-104438urn:isbn:978-91-7501-450-0TRITA-BIO-Report, 1654-2312 ; 2012:18application/pdfinfo:eu-repo/semantics/openAccess
collection NDLTD
language English
format Doctoral Thesis
sources NDLTD
topic Cancer
Mutations
Variations
Single Nucleotide Polymorphism
DNA
RNA
Genome
Massively Parallel Sequencing
Exome Sequencing
Toxicity
spellingShingle Cancer
Mutations
Variations
Single Nucleotide Polymorphism
DNA
RNA
Genome
Massively Parallel Sequencing
Exome Sequencing
Toxicity
Hasmats, Johanna
Analysis of genetic variations in cancer
description The aim of this thesis is to apply recently developed technologies for genomic variation analyses, and to ensure quality of the generated information for use in preclinical cancer research. Faster access to a patients’ full genomic sequence for a lower cost makes it possible for end users such as clinicians and physicians to gain a more complete understanding of the disease status of a patient and adjust treatment accordingly. Correct biological interpretation is important in this context, and can only be provided through fast and simple access to relevant high quality data. Therefore, we here propose and validate new bioinformatic strategies for biomarker selection for prediction of response to cancer therapy. We initially explored the use of bioinformatic tools to select interesting targets for toxicity in carboplatin and paclitaxel on a smaller scale. From our findings we then further extended the analysis to the entire exome to look for biomarkers as targets for adverse effects from carboplatin and gemcitabine. To investigate any bias introduced by the methods used for targeting the exome, we analyzed the mutation profiles in cancer patients by comparing whole genome amplified DNA to unamplified DNA. In addition, we applied RNA-seq to the same patients to further validate the variations obtained by sequencing of DNA. The understanding of the human cancer genome is growing rapidly, thanks to methodological development of analysis tools. The next step is to implement these tools as a part of a chain from diagnosis of patients to genomic research to personalized treatment. === <p>QC 20121105</p>
author Hasmats, Johanna
author_facet Hasmats, Johanna
author_sort Hasmats, Johanna
title Analysis of genetic variations in cancer
title_short Analysis of genetic variations in cancer
title_full Analysis of genetic variations in cancer
title_fullStr Analysis of genetic variations in cancer
title_full_unstemmed Analysis of genetic variations in cancer
title_sort analysis of genetic variations in cancer
publisher KTH, Genteknologi
publishDate 2012
url http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-104438
http://nbn-resolving.de/urn:isbn:978-91-7501-450-0
work_keys_str_mv AT hasmatsjohanna analysisofgeneticvariationsincancer
_version_ 1716637724201451520